En un paragraphe
Mammoth searches for and engineers unusually small CRISPR proteins. Size is the point: the standard delivery vehicle for in vivo therapy has a strict weight limit, and a smaller editor leaves room for everything else that has to travel with it. The same proteins also power rapid diagnostic tests.
Mammoth Biosciences was founded in 2017 by Jennifer Doudna, Trevor Martin, Janice Chen and Lucas Harrington. It develops ultracompact CRISPR systems including NanoCas for in vivo editing where AAV packaging limits bind, and CRISPR-based diagnostics derived from collateral cleavage activity.
Sources
- Mammoth Biosciences
Mammoth Biosciences ↗
Pas un conseil en investissement
Ce profil est une information éducative compilée à partir de communications publiques. Il ne constitue pas une recommandation d'acheter, de vendre ou de conserver un titre, et ne représente pas un avis sur les perspectives de l'entreprise. La biotechnologie est très spéculative et la plupart des programmes cliniques échouent.
Avertissements complets →